HUTCHMED (China) Limited (AIM: HCM)
London
· Delayed Price · Currency is GBP · Price in GBX
232.00
0.00 (0.00%)
Dec 30, 2024, 4:35 PM GMT+1
HUTCHMED (China) Revenue
HUTCHMED (China) had revenue of $305.68M USD in the half year ending June 30, 2024, with 51.29% growth. This brings the company's revenue in the last twelve months to $610.81M, down -19.34% year-over-year. In the year 2023, HUTCHMED (China) had annual revenue of $838.00M with 96.52% growth.
Revenue (ttm)
$610.81M
Revenue Growth
-19.34%
P/S Ratio
4.37
Revenue / Employee
$307.25K
Employees
1,988
Market Cap
2.11B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
Dec 31, 2020 | 227.98M | 23.09M | 11.27% |
Dec 31, 2019 | 204.89M | -9.22M | -4.31% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
Indivior | 881.89M |
Oxford Nanopore Technologies | 167.75M |
HUTCHMED (China) News
- 21 days ago - HUTCHMED (China) Ltd (HCM) Secures $10 Million Milestone Payment Following European ... - GuruFocus
- 21 days ago - HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) - GlobeNewsWire
- 21 days ago - HUTCHMED (China) Ltd (HCM) Receives Breakthrough Therapy Designation for Lung Cancer Treatment - GuruFocus
- 21 days ago - HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - GlobeNewsWire
- 4 weeks ago - Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer - PRNewsWire
- 4 weeks ago - HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer - GlobeNewsWire
- 5 weeks ago - HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms - GlobeNewsWire
- 5 weeks ago - HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan - GlobeNewsWire